Case study: Scalable manufacturing of iPSC-derived cardiomyocytes

Authors:

Eva D'Amico, PhD - Principal Scientist, Cell Therapy Innovation

Mélanie Duyck, PhD - Senior Process Engineer, MSAT

Abstract

In this case study, Cellistic presents the Echo™-Cardio use case, a suspension-based stirred-tank bioprocess for manufacturing iPSC-derived cardiomyocytes under chemically defined conditions. The platform achieves high cardiac purity, robust viable cell yields, and a predominantly ventricular-like phenotype, while avoiding dedicated downstream purification steps that can increase process complexity and limit scalability.